RAPT THERAPEUTICS INC
NASDAQ: RAPT (RAPT Therapeutics, Inc.)
Last update: 19 hours ago11.38
-0.08 (-0.70%)
| Previous Close | 11.46 |
| Open | 11.40 |
| Volume | 17,591 |
| Avg. Volume (3M) | 105,126 |
| Market Cap | 188,200,160 |
| Price / Sales | 411.22 |
| Price / Book | 1.09 |
| 52 Weeks Range | |
| Earnings Date | 7 Aug 2025 |
| Diluted EPS (TTM) | -19.84 |
| Total Debt/Equity (MRQ) | 2.16% |
| Current Ratio (MRQ) | 21.11 |
| Operating Cash Flow (TTM) | -108.63 M |
| Levered Free Cash Flow (TTM) | -65.95 M |
| Return on Assets (TTM) | -44.72% |
| Return on Equity (TTM) | -75.60% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | RAPT Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 1.0 |
| Average | 0.75 |
|
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 0.42% |
| % Held by Institutions | 99.41% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 30 Jun 2025 | 2,794,000 |
| Column Group Llc | 30 Jun 2025 | 1,328,613 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 38.00 (Wells Fargo, 233.92%) | Buy |
| Median | 27.00 (137.26%) | |
| Low | 9.00 (UBS, -20.91%) | Hold |
| Average | 23.80 (109.14%) | |
| Total | 3 Buy, 2 Hold | |
| Avg. Price @ Call | 10.59 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| UBS | 12 Aug 2025 | 9.00 (-20.91%) | Hold | 10.90 |
| Wells Fargo | 08 Aug 2025 | 38.00 (233.92%) | Buy | 9.81 |
| JP Morgan | 30 Jul 2025 | 14.00 (23.02%) | Hold | 11.32 |
| LifeSci Capital | 22 Jul 2025 | 31.00 (172.41%) | Buy | 12.28 |
| HC Wainwright & Co. | 10 Jul 2025 | 27.00 (137.26%) | Buy | 8.62 |
| Date | Type | Details |
|---|---|---|
| 27 Aug 2025 | Announcement | RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences |
| 07 Aug 2025 | Announcement | RAPT Therapeutics Reports Second Quarter 2025 Financial Results |
| 23 Jun 2025 | Announcement | RAPT Therapeutics Names Two Industry Veterans to its Board of Directors |
| 13 Jun 2025 | Announcement | RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split |
| 04 Jun 2025 | Announcement | RAPT Therapeutics to Participate in Upcoming Investor Conferences |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |